Study #2021-0786
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, And Efficacy of AMG 193 Alone and In Combination with Docetaxel in Subjects with Advanced MTAP-Null Solid Tumors
MD Anderson Study Status
Enrolling
Treatment Agent
AMG 193, Docetaxel, Comparator AMG 193 Test Tablet
Description
The primary objective of Parts 1 and 2 of this study is to evaluate the safety, tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of AMG 193 alone and in combination with docetaxel in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. The primary objective of Part 3 of this study is to evaluate the efficacy of AMG 193 in adult participants with metastatic or locally advanced MTAP-null solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced MTAP-null Solid Tumors
Study phase:
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-698-5449
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.